STERIS plc (NYSE:STE) Receives $239.60 Consensus Price Target from Analysts

STERIS plc (NYSE:STE) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $239.60.

STE has been the subject of a number of research reports. Morgan Stanley decreased their price objective on STERIS from $225.00 to $215.00 and set an “equal weight” rating for the company in a report on Monday, December 4th. Stephens reiterated an “overweight” rating and issued a $250.00 price objective on shares of STERIS in a report on Friday, February 9th. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Thursday, February 8th. TheStreet upgraded STERIS from a “c+” rating to a “b” rating in a report on Wednesday, February 7th. Finally, KeyCorp began coverage on STERIS in a report on Tuesday, February 6th. They set an “overweight” rating and a $253.00 price target for the company.

Institutional Investors Weigh In On STERIS

Several large investors have recently bought and sold shares of STE. Millburn Ridgefield Corp bought a new stake in STERIS in the 3rd quarter worth about $25,000. Catalyst Capital Advisors LLC bought a new stake in STERIS in the 3rd quarter worth about $25,000. 1832 Asset Management L.P. bought a new stake in STERIS in the 1st quarter worth about $25,000. West Tower Group LLC bought a new stake in STERIS in the 2nd quarter worth about $32,000. Finally, VisionPoint Advisory Group LLC bought a new stake in STERIS in the 4th quarter worth about $34,000. 94.69% of the stock is currently owned by institutional investors.

STERIS Stock Performance

NYSE:STE opened at $224.82 on Friday. The business has a 50 day moving average price of $227.09 and a 200-day moving average price of $219.16. STERIS has a fifty-two week low of $180.54 and a fifty-two week high of $254.00. The firm has a market cap of $22.21 billion, a PE ratio of 39.37 and a beta of 0.80. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.49 and a current ratio of 2.43.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $2.22 EPS for the quarter, topping analysts’ consensus estimates of $2.17 by $0.05. The company had revenue of $1.40 billion during the quarter, compared to analyst estimates of $1.35 billion. STERIS had a return on equity of 13.67% and a net margin of 10.48%. The firm’s revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.02 earnings per share. Equities research analysts predict that STERIS will post 8.67 earnings per share for the current year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Friday, February 23rd were issued a dividend of $0.52 per share. The ex-dividend date was Thursday, February 22nd. This represents a $2.08 annualized dividend and a dividend yield of 0.93%. STERIS’s payout ratio is presently 36.43%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.